Document is current

Article History

Received: 25 January 2025

Revised: 5 April 2025

Accepted: 11 April 2025

First Online: 19 September 2025

Ethics declaration

: The authors declare there are no conflicts of interest. This is a retrospective service evaluation and ethics approval was not required according to the Medical Research Council HRA toolkit. The retrospective nature of data collection meant that it had no influence on patient care/interventions. Consent was not required. Under NHS guidelines, all patients are informed that their data may be used for audit and monitoring purposes unless they choose to opt out. Additionally, all patients provided written consent for the use of remimazolam as part of their treatment plan. Both services have registered the service evaluation with their respective audit/clinical effectiveness unit (CEU).